Are we approaching personalised medicine in gynaecological cancers?

Speaker: Ignace Vergote

I. Vergote outlines key genomic changes in gynaecological malignancies relevant to clinical practice. He discusses the current status of targeted treatments and the prospect of targeting different pathways; biomarker research; the impact of commercial molecular tumour profiling and the discovery of actionable mutations, plus existing barriers in terms of patient access to personalised cancer medicine and what the future holds.

Discussion Points

  • Outline of key genomic changes in the spectrum of gynaecological malignancies, relevant to clinical practice
  • What is the current status of targeted treatments for gynaecological malignancies?
  • Where do we stand in terms of biomarker research in gynaecological tumours?
  • Impact of commercial molecular tumour profiling and the discovery of actionable mutations in gynaecological cancers
  • What specific barriers exist in terms of patient access to personalised medicine in gynaecological cancers?
  • What does the future hold for personalised treatments in this area?